oral semaglutide fda Approves as First GLP-1 Pill for Weight Loss FDA approves Novo Nordisk's oral
Description
doi: 10.2337/dc09-1203
Severe nausea, vomiting, constipation, abdominal bloating, and in rare cases, difficulty breathing are the primary risks
BPC-157 is most often discussed as potentially influencing some of those inputs
Ultimately, the decision to use semaglutide in Crohn's disease requires individualized risk-benefit analysis, and patients should never feel pressured to continue a medication that worsens their quality of life or disease control
Both groups exceeded 20%, and both experienced manageable side effect profiles
